Welcome to The Catalyst
Change isn't quick. Unless it's when you experience Intravascular Lithotripsy (IVL) for the first time. Stay apprised of our latest news and insights while discovering how a simple and intuitive tool can be The Catalyst to change the way you think about calcium modification.
Join us at TCT2024 in Washington DC where Shockwave Medical and our clinical partners will bring to life long-awaited innovations that move the field of IVL FORWARD! Visit the Shockwave booth and go hands-on with the highly anticipated Shockwave Javelin catheter and our latest peripheral catheter, Shockwave E8. Join colleagues at the Shockwave Symposium on Tuesday, October 29 where a panel of experts will show how you can veto challenging calcium by backing our latest calcium contenders.
Topics: Coronary IVL, IVL Technology, Shockwave C2, Coronary Conferences
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2
Q2 is in the books and it was full of electrifying news, big accomplishments and new beginnings. Of course, a major milestone was the acquisition of Shockwave Medical by Johnson & Johnson MedTech. This new journey is off to a great start and we’re excited about how this partnership will help us expand access to our life-changing technologies across the globe.
Updates from the Reducer team for our international physician partners include publishing new data that show positive news for patients suffering from Refractory Angina.* Additionally, our Size for Success training about sizing up for the best Peripheral IVL results is also gaining traction and was featured in several publications. Read the latest PulsePoint Newsletter to learn more about important milestones from Q2!
Topics: Coronary IVL, Peripheral IVL, IVL Technology, Coronary Clinical Data, Peripheral Conferences, Peripheral Clinical Data, SWAV News, Shockwave C2, Coronary Conferences, Shockwave S4, PulsePoint Newsletter, Calcium Corner, Shockwave M5 & Shockwave M5+, Reimbursement, Treating Different Ca++ Morphologies, Female vs. Male Outcomes, Empower CAD, Reducer
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2
There’s no better way to start a new year than building positive momentum. Between great developments on coronary reimbursement to positive real-world data for Reducer, 2024 is off to a shock-worthy start.
Another highlight was the continuous enrollment of patients in our EMPOWER CAD Study — the first prospective clinical study in the interventional space completely dedicated to female patients. Our team also created new resources about optimal sizing for Peripheral IVL, as well as put the final touches on our new manufacturing facility in Costa Rica. Read more about our strong start and get excited about what’s to come in the latest edition of the PulsePoint Newsletter.
Topics: Coronary IVL, Peripheral IVL, IVL Technology, Coronary Clinical Data, Peripheral Conferences, Peripheral Clinical Data, SWAV News, Shockwave C2, Coronary Conferences, Shockwave S4, PulsePoint Newsletter, Calcium Corner, Shockwave M5 & Shockwave M5+, Reimbursement, Treating Different Ca++ Morphologies, Female vs. Male Outcomes, Empower CAD, Reducer
Get your wetsuits ready because Shockwave's SCAI 2024 lineup will cause some serious waves in Long Beach. Take a look at the hot topics Shockwave has in store for you this year including:
Topics: Coronary IVL, IVL Technology, Shockwave C2, Coronary Conferences
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2
Enrollments in the EMPOWER CAD study are picking up pace! Dr Nieves Gonzalo (Hospital Clìnico San Carlos, Madrid), the study’s European lead, recently shared with the medical community the journey of her first patient included in the study.
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
